These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24237755)

  • 1. Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
    Duan XY; Wang W; Wang JS; Shang J; Gao JG; Guo YM
    BMC Cancer; 2013 Nov; 13():546. PubMed ID: 24237755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients.
    Bai L; Guo CH; Zhao Y; Gao JG; Li M; Shen C; Guo YM; Duan XY
    Oncol Rep; 2017 Jun; 37(6):3433-3440. PubMed ID: 28498457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fludrodeoxyglucose maximal standardized uptake value and metabolic tumor burden are associated with major chemotherapy-related tumor markers in NSCLC patients.
    Bai L; Guo C; Wang J; Liu X; Li Y; Li M; Guo Y; Duan X
    Onco Targets Ther; 2016; 9():6315-6324. PubMed ID: 27789962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.
    Taylor MD; Smith PW; Brix WK; Wick MR; Theodosakis N; Swenson BR; Kozower BD; Lau CL; Jones DR
    J Thorac Cardiovasc Surg; 2009 Jan; 137(1):43-8. PubMed ID: 19154901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
    Taylor MD; Smith PW; Brix WK; Wick MR; Theodosakis N; Swenson BR; Kozower BD; Jones DR
    Eur J Cardiothorac Surg; 2009 Apr; 35(4):699-705. PubMed ID: 19136271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.
    Tong AN; Han SR; Yan P; Gong H; Zhao H; Yao H; Wang YM
    Med Oncol; 2014 Jan; 31(1):780. PubMed ID: 24326983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer.
    Li C; Liu M; Yan A; Liu W; Hou J; Cai L; Dong X
    Tumour Biol; 2014 Dec; 35(12):12707-12. PubMed ID: 25217323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X; Guo Y; Qian X
    Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET parameters predicting mediastinal malignancy in lung cancer.
    Serra Fortuny M; Gallego M; Berna L; Montón C; Vigil L; Masdeu MJ; Fernández-Villar A; Botana MI; Cordovilla R; García-Luján R; Cases E; Monsó E
    BMC Pulm Med; 2016 Dec; 16(1):177. PubMed ID: 27931198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
    Cho A; Hur J; Moon YW; Hong SR; Suh YJ; Kim YJ; Im DJ; Hong YJ; Lee HJ; Kim YJ; Shim HS; Lee JS; Kim JH; Choi BW
    BMC Cancer; 2016 Mar; 16():224. PubMed ID: 26979333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
    Lee HW; Choi YW; Han JH; Kim JH; Jung JH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2009 Sep; 65(3):377-82. PubMed ID: 19150580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.
    Hyun SH; Ahn HK; Kim H; Ahn MJ; Park K; Ahn YC; Kim J; Shim YM; Choi JY
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):50-8. PubMed ID: 23948859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.